Antengene pockets USD 60m from UCB as it pivots to monetizing proprietary TCE platform

Antengene Corporation Limited (HKEX: 6996) has [confirmed receipt](https://www.prnewswire.com/news-releases/antengene-announces-receipt-of-usd-60-million-upfront-payment-from-ucb-302823509.html) of the USD 60 million upfront payment from UCB under their worldwide exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager targeting B cell-related autoimmune diseases. The cash receipt, announced July 13, 2026, converts a deal signed in March 2026 into realized revenue — a meaningful inflection for Antengene as it transitions from a company historically known for in-licensing Western assets to one systematically monetizing its own proprietary TCE platform. The [original March 2026 agreement](https://app.allsci.com/news/ASC-NR-0000000550085-1.0-1774444631) structured the Antengene UCB ATG-201 transaction as a full global out-license, with UCB acquiring worldwide exclusive rights to develop, manufacture, and commercialize the asset. Antengene retains no territorial commercialization rights. Under the terms, Antengene receives USD 80 million in upfront and near-term consideration — the USD 60 million upfront payment now confirmed received, plus USD 20 million in additional near-term milestone payments subject to undisclosed conditions. The company is also eligible for more than USD 1.1 billion in success-based development, regulatory, and sales milestones, along with tiered royalties on future net sales. Specific milestone breakdowns and royalty rates were not disclosed. ATG-201 is described by Antengene as a CD19×CD3 bispecific TCE antibody built on its proprietary AnTenGager platform, which incorporates a "2+1" format — two CD19-binding arms and one CD3-binding arm — combined with steric hindrance masking technology designed to restrict T-cell activation to the presence of CD19-expressing target cells. The company presented preclinical data at ACR 2025 in October 2025, [showing](https://app.allsci.com/news/ASC-NR-0000000564424-1.0-1774444646) CD19-dependent CD3 binding, complete B-cell depletion in humanized mouse models, and a favorable safety profile in non-human primates at doses of 1–6 mg/kg with only mild, transient cytokine elevation. No Phase I human data existed at deal signing. Since the license was executed, ATG-201's regulatory status has advanced. China's National Medical Products Administration [approved the IND application](https://app.allsci.com/news/ASC-NR-0000003825581-1.0-1781053571) for the Phase I ATTRACT study in June 2026. Antengene plans to conduct first-in-human studies in China and Australia before transferring further clinical development to UCB. For Antengene, the confirmed USD 60 million cash receipt materially strengthens a balance sheet that held approximately RMB 734 million (approximately USD 100 million) at end of 2025. The company has described the UCB transaction as an inflection point toward 2026 profitability, with the AnTenGager platform now generating two out-licensing transactions within four months. The NMPA IND approval for ATG-201 in June 2026 adds a near-term clinical catalyst that may trigger the USD 20 million near-term milestone payment, though the specific conditions for that tranche have not been publicly disclosed. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/antengene-ucb-60-million-deal-pockets-usd-60m)